With the business potentially at an important milestone, we thought we'd take a closer look at Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) future prospects. Zevra Therapeutics, Inc. discovers and ...
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm ...
Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, ...
Hosted on MSN15d
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketThe agency handed the first approval to a drug called Miplyffa from Zevra Therapeutics, which reached the finish line on the ...
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying ...
An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.
Zevra Therapeutics' Miplyffa has become the first medicine to be approved by the FDA for the ultra-rare genetic disorder Niemann-Pick disease. The US regulator has cleared Miplyffa (arimoclomol ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback